Protalix BioTherapeutics, Inc. (DE)

As of June 30, 2026, Protalix Biotherapeutics, Inc. carries a market capitalization of 165.17M, placing it among publicly traded companies globally. Its enterprise value stands at 137.64M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Protalix Biotherapeutics, Inc.'s next confirmed earnings release is scheduled for November 16, 2026.

As of June 30, 2026, Protalix Biotherapeutics, Inc. has 80.57M shares outstanding.

As of June 30, 2026, Protalix Biotherapeutics, Inc. trades at a trailing price-to-earnings ratio of 9.88. The price-to-sales ratio is 2.32, and the price-to-book ratio stands at 2.64.

As of June 30, 2026, Protalix Biotherapeutics, Inc. trades at an EV/EBITDA multiple of 6.33 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.95 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 6.75 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Protalix Biotherapeutics, Inc. trades at an EV/FCF ratio of 18.12, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 137.64M versus a market cap of 165.17M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Protalix Biotherapeutics, Inc. maintains a current ratio of 2.94, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 12.89, indicating elevated leverage, while an interest coverage ratio of 19.89 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Protalix Biotherapeutics, Inc. posted a return on equity (ROE) of 31.23, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 26.15 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 20.07, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 29.37, useful for judging operating efficiency across full business cycles. The company generates approximately 316,793.76 in revenue per employee across its workforce of 222.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.93 indicates how many times Protalix Biotherapeutics, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Protalix Biotherapeutics, Inc. recorded 3.96M in income tax expense. That works out to an effective tax rate of 19.26, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 20.54M, leaving 16.58M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Protalix Biotherapeutics, Inc.'s stock has gained approximately 18.75% over the past 52 weeks. The 50-day moving average sits at 2.29, while the 200-day moving average is 2.07.

Over the twelve months ended June 30, 2026, Protalix Biotherapeutics, Inc. generated 70.57M in revenue and converted that into 16.58M in net income, yielding earnings per share of 0.20. EBITDA reached 21.76M, while operating income came in at 20.39M.

As of June 30, 2026, Protalix Biotherapeutics, Inc. holds 35.59M in cash and equivalents against 8.06M in total debt, resulting in a net debt position of -24.00M. Total book value stands at 62.50M, with working capital of 53.24M providing operational flexibility.

Protalix Biotherapeutics, Inc. produced 8.69M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.97M in capital expenditures, free cash flow totaled 6.71M - equivalent to 0.08 per share.

Over the twelve months ended June 30, 2026, Protalix Biotherapeutics, Inc. posted a gross margin of 69.20, reflecting its pricing power and cost economics. The operating margin of 28.89 and net profit margin of 23.50 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 4.01, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -0.16, meaning Protalix Biotherapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Protalix Biotherapeutics, Inc.'s most recent stock split took place on December 20, 2019 with a 10:1 split ratio.

As of June 30, 2026, Protalix Biotherapeutics, Inc. has an Altman Z-Score of 0.39, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.